RenovoRx, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
RNXT$1.18+4.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. FORM 10-K SUMMARY
None.
EXHIBIT INDEX
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| Exhibit No. | Exhibit Description | Form | File No. | Exhibit | Filing Date |
| 3.1 | Sixth Amended and Restated Certificate of Incorporation of RenovoRx, Inc. | 8-K | 001-40738 | 3.1 | August 31, 2021 |
| 3.2 | Amended and Restated Bylaws of RenovoRx, Inc. | 8-K | 001-40738 | 3.1 | September 11, 2023 |
| 4.1 | Form of Private Common Stock Warrant (related to the 2020 Convertible Notes and 2021 Convertible Notes) | 10-Q | 001-40738 | 4.1 | November 15, 2021 |
| 4.2 | Form of Underwriter’s Warrant | S-1 | 333-258071 | 4.1 | August 25, 2021 |
| 4.3 | Form of Warrant Agent Agreement (including the terms of the Warrants) | S-1 | 333-258071 | 4.2 | August 25, 2021 |
| 4.4 | Specimen Stock Certificate evidencing the Shares of Common Stock | S-1 | 333-258071 | 4.4 | August 25, 2021 |
| 4.5 | Form of Warrant Certificate | S-1 | 333-258071 | 4.5 | August 25, 2021 |
| 4.6 | Form of Pre-Funded Common Stock Purchase Warrant | 8-K | 001-40738 | 4.1 | April 3, 2023 |
| 4.7 | Form of Common Stock Purchase Warrant | 8-K | 001-40738 | 4.2 | April 3, 2023 |
| 4.8 | Form of Warrant to Purchase Common Stock Issued in January 2024 Private Placement | 8-K | 001-40738 | 10.3 | January 29, 2024 |
| 4.9 | Form of Placement Agent Warrant Issued in January 2024 Private Placement | 8-K | 001-40738 | 10.5 | January 29, 2024 |
| 4.10 | Form of Pre-Funded Common Stock Purchase Warrant issued in April 2024 Private Placement | 8-K | 001-40738 | 10.2 | April 15, 2024 |
| 4.11 | Form of Series A Warrant to Purchase Common Stock issued in April 2024 Private Placement | 8-K | 001-40738 | 10.3 | April 15, 2024 |
| 4.12 | Form of Series B Warrant to Purchase Common Stock issued in April 2024 Private Placement | 8-K | 001-40738 | 10.4 | April 15, 2024 |
| 4.13 | Form of Placement Agent Warrant to Purchase Common Stock issued in April 2024 Private Placement | 8-K | 001-40738 | 10.5 | April 15, 2024 |
| 4.14 | Common Stock Purchase Warrant Issued to Medical Murray, Inc., dated September 25, 2024 | 10-Q | 001-40738 | 4.14 | November 13, 2024 |
| 4.15 | Form of Underwriter Warrant issued in February 2025 Public Offering | 8-K | 001-40738 | 4.1 | February 10, 2025 |
| 4.16 | Description of Securities | 10-K | 001-40738 | 4.6 | March 30, 2022 |
| 4.17 | Form of Pre-Funded Warrant Issued to Investors in the March 2026 Private Placement | 8-K | 001-40738 | 4.1 | March 23, 2026 |
| 4.18 | Form of Milestone Warrant Issued to Investors in the March 2026 Private Placement. | 8-K | 001-40738 | 4.2 | March 23, 2026 |
| 10.1 | Amended and Restated Investor Rights Agreement, dated as of April 18, 2018 | 10-Q | 001-40738 | 10.1 | November 15, 2021 |
| 10.2† | Amended and Restated 2021 Omnibus Equity Incentive Plan and Forms of Stock Option Grant Notice and Option Agreement | 10-Q | 001-40738 | 10.1 | August 14, 2025 |
| 10.3† | Amended and Restated Outside Director Compensation Policy | 10-K | 001-40738 | 10.3 | April 1, 2024 |
| 10.4† | Confirmatory Offer Letter, by and between RenovoRx, Inc. and Shaun Bagai, dated November 11, 2021 | 10-Q | 001-40738 | 10.4 | November 15, 2021 |
| 10.5† | Consulting Agreement, by and between RenovoRx, Inc. and Ramtin Agah, M.D., dated January 1, 2018 | 10-Q | 001-40738 | 10.5 | November 15, 2021 |
| 10.6† | Amendment to Consulting Agreement, by and between RenovoRx, Inc. and Ramtin Agah, M.D., dated November 11, 2021 | 10-Q | 001-40738 | 10.6 | November 15, 2021 |
| 10.7† | Amendment to Consulting Agreement, by and between RenovoRx, Inc. and Ramtin Agah, M.D., dated January 25, 2022 | 10-K | 001-40738 | 10.7 | March 30, 2022 |
| 10.8† | Amended and Restated Change in Control and Severance Agreement, by and between RenovoRx, Inc. and Shaun Bagai, dated November 10, 2025 | 10-Q | 001-40738 | 10.1 | November 13, 2025 |
| 10.9† | Amended and Restated Change in Control and Severance Agreement, by and between RenovoRx, Inc. and Ramtin Agah, dated November 10, 2025 | 10-Q | 001-40738 | 10.2 | November 13, 2025 |
| 10.10† | Key Service Provider Incentive Compensation Plan | 10-Q | 001-40738 | 10.9 | November 15, 2021 |
| 10.11† | Form of Indemnification Agreement | S-1 | 333-258071 | 10.7 | August 25, 2021 |
| 10.12+ | Supply Agreement, dated June 5, 2025, between RenovoRx, Inc. and Medical Murray, Inc. | 10-Q | 001-40738 | 10.2 | August 14, 2025 |
| 10.13† | Amended and Restated Change in Control and Severance Agreement, by and between RenovoRx, Inc. and Ronald Kocak, dated November 10, 2025 | 10-Q | 001-40738 | 10.3 | November 13, 2025 |
| 10.14† | Amended and Restated Change in Control and Severance Agreement, by and between RenovoRx, Inc. and Leesa Gentry, dated November 10, 2025 | 10-Q | 001-40738 | 10.4 | November 13, 2025 |
| 10.15†# | Consulting Agreement, dated February 4, 2026, by and between RenovoRx, Inc. and Mark Voll | 8-K | 001-40738 | 10.1 | February 6, 2026 |
| 10.16† | Form of Placement Agency Agreement by and between RenovoRx, Inc. and Roth Capital Partners, LLC, dated March 30, 2023 | 8-K | 001-40738 | 10.1 | April 3, 2023 |
| 10.17† | Form of Securities Purchase Agreement | 8-K | 001-40738 | 10.2 | April 3, 2023 |
| 10.18 | Subscription Agreement, by and between RenovoRx, Inc. and the investors thereto | 8-K | 001-40738 | 10.1 | January 29, 2024 |
| 10.19 | Offering Extension, dated January 12, 2024 | 8-K | 001-40738 | 10.2 | January 29, 2024 |
| 10.20 | Placement Agent Agreement, by and between RenovoRx, Inc. and Paulson Investment Company, LLC, dated November 14, 2023 | 8-K | 001-40738 | 10.4 | January 29, 2024 |
| 10.21 | Amended and Restated Offer Letter, by and between RenovoRx, Inc. and Ronald B. Kocak | 8-K | 001-40738 | 10.1 | February 9, 2024 |
| 10.22 | Amended and Restated Offer Letter, by and between RenovoRx, Inc. and Leesa Gentry | 8-K | 001-40738 | 10.1 | March 14, 2024 |
| 10.23 | Form of Subscription Agreement (April 2024 Private Placement) | 8-K | 001-40738 | 10.1 | April 15, 2024 |
| 10.24† | Form of Securities Purchase Agreement in the March 2026 Private Placement | 8-K | 001-40738 | 10.1 | March 23, 2026 |
| 10.25† | Agah Offer Letter, dated March 24, 2026 and effective February 27, 2026, by and between RenovoRx, Inc. and Ramtin Agah | 8-K | 001-40738 | 10.1 | March 27, 2026 |
| 19.1 | Insider Trading Policy | 10-K | 001-40738 | 19.1 | April 1, 2024 |
| 23.1 | Consent of Frank, Rimerman + Co. LLP | Filed herewith | |||
| 31.1 | Certification of Principal Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a). | Filed herewith | |||
| 31.2 | Certification of Principal Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a). | Filed herewith | |||
| 32.1* | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350. | Furnished herewith | |||
| 32.2* | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350. | Furnished herewith | |||
| 97.1 | Policy Related to Recovery of Erroneously Awarded Compensation, adopted September 7, 2023 | 10-K | 001-40738 | 97.1 | April 1, 2024 |
| 101.INS | Inline XBRL Instance Document-the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document | Filed herewith | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents | Filed herewith | |||
| 104 | Cover Page formatted as Inline XBRL and contained in Exhibit 101 | Filed herewith | |||
† Indicates management contract or compensatory plan or arrangement
- Confidential portions of this Exhibit were redacted pursuant to Item 601(b)(2) of Regulation S-K and RenovoRx, Inc. agrees to furnish supplementally to the Securities and Exchange Commission a copy of any redacted information or omitted schedule and/or exhibit upon request.
Certain information has been omitted from this exhibit pursuant to Item 601(a)(6) or Item 601(b)(10)(iv) of Regulation S-K.
- The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report on Form 10-K are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report, irrespective of any general incorporation language contained in such filing.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.